Prolonged follow-up period following intravitreal bevacizumab injection for stage 3+ retinopathy of prematurity

@article{Klerk2013ProlongedFP,
  title={Prolonged follow-up period following intravitreal bevacizumab injection for stage 3+ retinopathy of prematurity},
  author={T. A. de Klerk and Do Young Park and Susmito Biswas},
  journal={Eye},
  year={2013},
  volume={27},
  pages={1218-1218}
}
Data from the Beat-ROP study indicate that bevacizumab (Avastin; Genentech Inc., South San Francisco, CA, USA) treatment results in a lower rate of retreatment compared with conventional laser treatment for Zone 1 retinopathy of prematurity (ROP).1 However, the suppression of angiogenesis means that follow-up until vascularisation into Zone 3 can be dramatically prolonged, as it was with the case we present here.